Our News

All the latest company news, views and insight from the Beckley Psytech team.

The Science Explained

Spotlight on the psychedelic experience

We continue our look back at the heritage of the Beckley Foundation’s ground-breaking research programmes and the potential for Beckley Psytech, which leverages the Foundation’s knowledge and research capabilities through a close strategic partne... Read More

In The News

Beckley Psytech’s CEO Cosmo Feilding Mellen comments on 5-MeO-DMT’s potential to rival psilocybin as a cost-effective psychedelic treatment for depression and addiction.  

In The News

Exclusive news article on the Beckley Psytech’s partnership with Fluence to develop a psychedelic-assisted psychotherapy training programme for 5-MeO-DMT, featuring quotes from CEO Cosmo Feilding Mellen and Chief Medical Advisor Dr Fiona Dunbar.

Company Announcements

Beckley Psytech partners with Fluence to create psychedelic therapy training programme

In The News

News article on the appointment of Adam George as Beckley Psytech’s new Independent Director, bringing nearly two decades of experience in the pharmaceuticals industry to the Board.

Company Announcements

Former GW Pharmaceuticals CFO joins Beckley Psytech’s Board

Interviews

Cosmo Feilding Mellen on Beckley Psytech’s plans for 2021

Q&A with Beckley Psytech CEO Cosmo Feilding Mellen

The Science Explained

Spotlight on Beckley Psytech and psilocybin

Our latest series looks at the heritage of the Beckley Foundation’s groundbreaking research programmes and the potential for Beckley Psytech, which leverages the Foundation’s knowledge and research capabilities through a close strategic partnersh... Read More

The Science Explained

Understanding 5-MeO-DMT: Historical use

Part Two: Animals

In The News

Article featuring Beckley Psytech among the European companies set to dominate the psychedelic medicine market, with comments from CEO Cosmo Feilding-Mellen.